<--Back to Faculty Listing
Afzal A. Siddiqui, PhD
Grover E. Murray Distinguished Professor
Department of Internal Medicine; Pathology; Immunology and Molecular Microbiology
Director, Center for Tropical Medicine and Infectious Diseases
Fulbright-Nehru Teaching & Research Scholar (2012-2013)
Afzal A. Siddiqui, PhD
Dr. Afzal Siddiqui is a tenured Professor of Immunology and Molecular Microbiology; Internal Medicine; and Pathology at the Texas Tech University School of Medicine. He is the Director of Center for Tropical Medicine and Infectious Diseases. He is also the Clinical Professor of Pharmacy Practice in the TTUHSC School of Pharmacy. Before joining TTUHSC, Dr. Siddiqui served as the Chief of Parasite Immunology at the East Tennessee State University School of Medicine and a Research Health Scientist in the Department of Veterans Affairs. He earned BS, MS and M.Phil. degrees from Aligarh University in India and his PhD from the University of Western Ontario in Canada. His professional training is from the Centers for Disease Control and Prevention, Morehouse College, University of Illinois College of Medicine, and Harvard School of Public Health. In the last 5 years, Dr. Siddiqui has obtained research support from the National Institute of Allergy and Infectious Disease, National Institutes of Health and other agencies totaling about $3.5 million. His research has previously been funded by National Research Council of Canada, National Foundation for Infectious Diseases, Thrasher Research Fund and Health Resources and Services Administration, among others. He has authored over 57 peer-reviewed publications and numerous book chapters/reviews. Dr. Siddiqui serves on the Editorial Board of Parasitology Research, Pathogen and Global Health and Scientific World Journal. He has served as peer-reviewer for over 40 international journals. He has served on numerous NIAID and NIH study sections. He serves as a consultant to the Immunology Devices Panel and General Hospital and Personal Use Devices Panel, US Food and Drug Administration. He has reviewed grants for Ministry of Labor, Health and Social Policies, Republic of Italy; Romanian National Council for Scientific Research; National Health and Medical Research Council, Australia. “In recognition of exceptional accomplishment in research and scholarship”, Dr. Siddiqui has been awarded Dean’s, President’s and Chancellor’s Council Research Awards from the School of Medicine, Texas Tech University Health Sciences Center and Texas Tech University System, respectively. “In recognition of several years of sustained excellence in teaching”, he has been awarded Dean’s Teaching Award for School of Medicine. He has recently been awarded the prestigious Fulbright Research and Teaching Award for Southeast Asia. The Fulbright Program is an international educational exchange program sponsored by the U.S. government and is designed to “increase mutual understanding between the people of the United States and the people of other countries.”
Dr. Siddiqui’s research interests include: Vaccine discovery, development and testing for human parasite Schistosoma mansoni and Stronglyloides stercoralis hyperinfection.
For over 20 years Dr. Siddiqui and his group has been working toward developing a vaccine against the human parasitic disease, schistosomiasis. This disease afflicts over 200 million people in 76 different countries; and an additional 800 million people are at risk of acquiring the infection. There is no vaccine available to protect against this infection. His group has identified a vaccine candidate, Sm-p80, which plays a pivotal role in the surface membrane renewal of schistosomes, a phenomenon employed by hemo-helminths to evade host immunity. They have tested prophylactic and therapeutic efficacy of Sm-p80-based vaccine formulations in mouse and nonhuman primate models. Their published data indicate that Sm-p80 is now ready to be moved into the next phase, i.e., Process Development, Formulation, Stability/Potency Testing, cGMP manufacture leading to IND filing with the final goal of Phase I/II human clinical trials. Dr. Siddiqui holds a US and international patent on Schistosomiasis Vaccine Compositions and Methods of Use. The development of a schistosome vaccine would be a major breakthrough and as the first anti-helminth vaccine could impact up to 1 billion people. An effective schistosome vaccine would contribute significantly toward reducing the disease spectrum and transmission of schistosomiasis.
Dr. Siddiqui’s other research interest is on the parasitic disease, strongyloidiasis. His work has led to the hypothesis that the major cause of hyperinfection with Strongyloides stercoralis is due to the direct effect of corticosteroids on the parasite and not necessarily due to the general immune suppression of the host by corticosteroids. To elucidate this phenomenon we have isolated a corticosteroid receptor from S. stercoralis which is a dauer larva formation gene 12 (daf-12). We are studying the role of daf-12 in the development of hyperinfection. Further the most cited review in the field of “Strongyloides stercoralis” is also authored by Dr. Siddiqui.
- Nonhuman primate and rodent models for infection/disease and vaccine efficacy
- Biological – Parasite Life cycles
- Immunological – ELISA, ELISPOT, FACS
- Molecular – RealTime PCR, Cloning, Expression (Prokaryotic and Eukaryotic)
- Siddiqui AA, Siddiqui BA & Ganley-Leal, L. 2011. Schistosomiasis Vaccines. Human Vaccines 7: 1192-1197.
- Ahmad G., Zhang W., Torben W., Ahrorov A., Damian RT., Wolf RF., White GL., Carey DW, Mwinzi PNM., Ganley-Leal L., Kennedy RC., & Siddiqui AA. 2011. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. Journal of Infectious Diseases 204:1437-1449.
- Zhang W., Ahmad G., Torben W., Noor Z., Le L., Damian RT., Wolf RF., White GL., Chavez-Suarez, M., Podesta, RB., Kennedy RC., & Siddiqui A.A. 2010. Sm-p80 based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. Journal of Infectious Diseases 201: 1105-1112.
- Ahmad G., Zhang W., Torben W, Damian RT., Wolf RF., White GL., Chavez-Suarez, M., Kennedy RC, & Siddiqui A.A. 2009. Protective and antifecundity effects of Sm-p80 based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 27: 2830-2837.
- Siddiqui, A. A. & Berk, S.L. 2001. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis. 33:1040 1047.
For a partial list of publications by Afzal A. Siddiqui in PubMed click here